Clinical trial
Assessment of Tartrate-Resistant Acid Phosphatase (TRAP) as a Bone Resorption…
NCT00264082 · University of Louisville, Other · Completed
Key facts
| NCT number | NCT00264082 |
|---|---|
| Title | Assessment of Tartrate-Resistant Acid Phosphatase (TRAP) as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis |
| Official title | "Tartrate-Resistant Acid Phosphatase as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis During Zometa Treatment: A Pilot Study" |
| Lead sponsor | University of Louisville, Other |
| Collaborators | James Graham Brown Cancer Center |
| Status | Completed |
| Study type | Observational |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Zometa(drug) |
| Enrollment | 30 |
| Start date | Sep 1, 2004 |
| Primary completion | May 1, 2006 |
| First posted | Dec 12, 2005 |
| Last update posted | Dec 29, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: